Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
893.2 USD | +0.08% | -1.62% | +1.63% |
04-26 | Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says | MT |
04-26 | Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.63% | 96.29B | |
-3.18% | 102B | |
+2.13% | 22.18B | |
-15.60% | 21.2B | |
-9.21% | 18.31B | |
-39.98% | 17.38B | |
-15.75% | 16.36B | |
+4.77% | 13.97B | |
+32.23% | 12.17B | |
+309.43% | 8.32B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Regeneron Secures European Commission Approval for Antibody Cocktail to Treat, Prevent COVID-19